Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07017478 · ClinicalTrials.gov registry record · Early Phase 1
Mood Effects of Serotonin Agonists: Depression
A Early Phase 1 study of Depression and Major Depressive Disorder, sponsored by University of Chicago.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT07017478: Recruiting Early Phase 1 study of Depression and Major Depressive Disorder, sponsored by University of Chicago.
NCT07017478 is a Early Phase 1 study of Depression and Major Depressive Disorder that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 48 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07017478, a Early Phase 1 study of Depression and Major Depressive Disorder, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression. The investigators will assess the relationship between mood-related symptoms and EEG as a neurophysiological marker.
Primary Outcome
Acute (Profile of Mood States scale ratings from 0-60).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LSD
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2026-06-01 |
| Phase | Early Phase 1 |
What NCT07017478 shows while recruiting
NCT07017478 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07017478 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT07017478 about?
NCT07017478 is a clinical study titled "Mood Effects of Serotonin Agonists: Depression". This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression. The investigators will assess the relationship between mood-related symptoms and EEG as a neurophysiological marker.
What is the current status of trial NCT07017478?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2025-06-09. Estimated completion is 2026-06-01.
What conditions does trial NCT07017478 study?
This clinical trial studies the following conditions: Depression, Major Depressive Disorder, LSD.
What interventions are being tested in trial NCT07017478?
The interventions under investigation include: Placebo (DRUG), LSD (DRUG).
Who is sponsoring clinical trial NCT07017478?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07017478 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07017478's enrollment target sits among peer trials
48 482nd of 679 higher than 197 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
Confirmatory Efficacy Trial of Attention Bias Modification for Depression
RECRUITING · Early Phase 1
-
A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
RECRUITING · Early Phase 1
-
Probiotic Administration for Adolescent Depression
RECRUITING · Early Phase 1
-
Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)
ACTIVE NOT RECRUITING · Early Phase 1
-
Testing a Transdiagnostic TMS Treatment Target
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy